^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.

Published date:
05/25/2023
Excerpt:
105 pts with advanced KRAS G12C-mutant NSCLC treated with sotorasib were identified….Dual STK11/KEAP1 co-mutation status was associated with shorter OS compared to STK11 wild-type (WT)/KEAP1 mutant (MUT) status (OS HR 4.04, P = 0.033) and STK11 MUT/KEAP1 WT status (OS HR 5.41, P = 0.012).
DOI:
10.1200/JCO.2023.41.16_suppl.9083